Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mark Tungesvik (NPI 1497723472)

Field	Value
Entity Type	Individual
Organization	Mark Tungesvik
Address	1705 E Broadway
City	Columbia
State	MO
ZIP	65201
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 8, 2006

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

This provider is effectively a single‑payer Medicare biller: lifetime Medicare revenue is $3.3M while Medicaid activity is listed as none, so all observed public-payer billing in the file is Medicare-based. That concentration means analyses of payer mix, reimbursement risk, and access should focus on Medicare beneficiaries and fee schedules.

Revenue is highly concentrated in a small set of oncology drug administrations: the precomputed top 3 codes by revenue account for 63.1% of this provider's total Medicare revenue, with J9271 alone representing $1.4M (43.4% of Medicare revenue). This degree of concentration indicates the practice’s financial performance is heavily dependent on high-cost immunotherapy infusions.

Clinical/service-line mix points to an infusion-based hematology/oncology practice oriented toward checkpoint inhibitors and monoclonal antibodies: the top revenue drivers are J9271 (pembrolizumab), J9299 (nivolumab), and J9144 (daratumumab), and supportive/ancillary oncology items such as J0897 (denosumab) and J0881 (darbepoetin) also appear in the top codes. The code mix (large volumes of infusion drugs plus chemotherapy administration codes like 96413) is consistent with an outpatient infusion center or oncology clinic that manages systemic cancer therapies and related supportive care.

Competitive standing is mixed across specific products: for J9271 the provider ranks #99 of 1841 providers nationally (95th percentile) and is reported as notably above typical national volume for that code, indicating a relatively prominent national position for pembrolizumab administration. By contrast, other high-revenue oncology agents such as J9299 (rank #247 of 505, 51th percentile) and J9144 (rank #362 of 615, 39th percentile) show more typical or modest national volumes, so the provider’s prominence is concentrated on a subset of agents.

High visit and chemotherapy administration volumes corroborate active ambulatory oncology practice: E/M codes 99214 ($92.4K, rank #10435 of 479517, 98th percentile, notably above typical national volume) and 99213 ($40.9K, rank #14054 of 457151, 97th percentile, notably above typical national volume) plus chemotherapy administration 96413 ($51.6K, rank #437 of 7514, 94th percentile, notably above typical national volume) suggest sustained patient-facing clinic throughput in addition to infusion revenue. These elevated percentiles for office visits and chemo administration support the inference of a busy outpatient oncology service line.

Use of advanced diagnostic imaging and novel PET tracers appears in the billing mix: 78815 (PET/CT) generated $72.2K and A9595 (piflufolastat f-18) generated $61.5K, indicating either on-site access or close referral relationships for PET imaging. Both codes are within typical national volume ranges (78815 rank #2810 of 6566, 57th percentile; A9595 rank #399 of 528, 22th percentile), so imaging supports the treatment workflow but is not an outsized national outlier for this provider.

Provider tenure is long-standing in the Medicare market: the NPI was enumerated 2006-03-08 (~20 years ago), which is consistent with an established practice and may help explain steady referral patterns and higher volumes for selected agents. This longevity should be considered when benchmarking growth, referral networks, or transitions in service mix.

There are contrasting national rank outliers at the low end for some small-revenue codes that warrant caution when interpreting counts: for example, J0641 appears as rank #12 of 13 providers nationally (8th percentile) despite contributing only $25.6K, and J1437 shows rank #564 of 581 (0th percentile) with $17.6K. These low-rank, low-dollar codes indicate uneven national distribution for certain ancillary items and underscore that high percentile or rank observations on small-dollar codes can reflect concentrated reporting rather than core business volume.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

67 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,200	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	14,980	$20	$359.5K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,020	$40	$266.8K
J9173	Injection, durvalumab, 10 mg	4,200	$60	$260.4K
J0897	Injection, denosumab, 1 mg	10,320	$20	$185.8K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,900	$30	$98.6K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	47,330	$1	$94.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,040	$90	$92.4K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	70	$1,030	$72.2K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	130	$490	$61.5K

Showing 1–10 of 67

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 67 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Mark Tungesvik — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

67 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	40	9,100	$40	$502K
J9299	10	20	14,170	$20	$360.3K
J9144	13	20	7,200	$40	$308.4K
J9173	1	10	3,820	$60	$215.9K
J1568	3	10	2,900	$30	$103.8K
J0897	21	210	2,400	$20	$82.4K
J0881	4	10	15,500	$1	$63.1K
A9595	1	10	100	$490	$52.7K
J1437	9	10	2,500	$20	$43.5K
Q5116	4	10	1,840	$20	$36.9K

Showing 1–10 of 67

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mark Tungesvik, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Liana Makarian	MO	Hematology & Oncology Physician	$3.3M	$0
Umasankar Ramadoss	MO	Hematology & Oncology Physician	$3.3M	$0
Elangovan Balakrishnan	MO	Hematology & Oncology Physician	$3.1M	$0
Andrew Iliff	MO	Hematology & Oncology Physician	$2.8M	$0
Mark Bryer	MO	Radiation Oncology Physician	$638K	$0
Reed Cope	MO	Radiation Oncology Physician	$572.2K	$0
Alexandre Tungesvik	MO	Hematology & Oncology Physician	$569.8K	$0
Harold Johnson	MO	Radiation Oncology Physician	$542.5K	$0
Hunter Nolen	MO	Urology Physician	$359.5K	$0
Andrew Leiker	MO	Radiation Oncology Physician	$303.9K	$0

Nearby Providers

Other providers in the same ZIP code as Mark Tungesvik, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Woodhaven	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$88.3M
Palmer's Home Care, LLC	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$82.3M
Oats, Inc.	MO	Non-emergency Medical Transport (VAN)	$0	$23.4M
Independent Living Center Of Mid-missouri Inc.	MO	Specialist	$0	$14.2M
Ch Allied Services, Inc.	MO	General Acute Care Hospital	$0	$8.6M
Central Missouri Area Agency On Aging	MO	Voluntary or Charitable Agency	$0	$8.4M
Life Christain Outreach	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$7.1M
Surgical Center At Columbia Orthopaedic Group LLC	MO	Ambulatory Surgical Clinic/Center	$6.2M	$0
Mid-missouri Supported Living	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$5.3M
Woodhaven Learning Center	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$5.1M

Mark Tungesvik — Billing Profile & Reimbursement Data

Sign up for Mark Tungesvik — Billing Profile & Reimbursement Data policy alerts

Mark Tungesvik — Billing Profile & Reimbursement Data

Sign up for Mark Tungesvik — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References